Epclusa (Sofosbuvir/Velpatasvir) Patent Expiration, LOE Window & CMS Spending
Epclusa (Sofosbuvir/Velpatasvir) by Gilead Sciences: FDA Orange Book core substance LOE 2033-05-16 (last listed 2034-07-30), 0 AB generics, $852.1M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Gilead Sciences |
| FDA Application & Pathway | N208341 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2033-05-16 |
| Last Listed Patent or Exclusivity Date | 2034-07-30 |
| Orange Book Patents (*PED Extensions) | 30 patents (15 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $852.1M |
| 2024 Medicare Part D Spend | $758.0M |
| 2024 Medicaid Spend | $94.0M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.